Unknown

Dataset Information

0

Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction.

ABSTRACT: Acebilustat is a new once-daily oral antiinflammatory drug in development for treatment of cystic fibrosis (CF) and other diseases. It is an inhibitor of leukotriene A4 hydrolase; therefore, production of leukotriene B4 (LTB4) in biological fluids provides a direct measure of the pharmacodynamic (PD) response to acebilustat treatment. Here we compare the pharmacokinetics (PK) and PD between CF patients and healthy volunteers, and investigate the food effect and CYP3A4 induction in healthy volunteers. No significant differences between study populations were observed for peak plasma level (Cmax ) or exposure (AUC). In healthy volunteers, a shift in time to Cmax (Tmax ) was observed after a high-fat meal, but there was no change in AUC. LTB4 production was reduced in the blood of both populations and in sputum from CF patients. Acebilustat did not induce CYP3A4. These results support continued clinical study of once-daily oral acebilustat in CF at doses of 50 and 100 mg.

SUBMITTER: Elborn JS 

PROVIDER: S-EPMC5351008 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction.

Elborn J S JS   Bhatt L L   Grosswald R R   Ahuja S S   Springman E B EB  

Clinical and translational science 20161028 1

Acebilustat is a new once-daily oral antiinflammatory drug in development for treatment of cystic fibrosis (CF) and other diseases. It is an inhibitor of leukotriene A4 hydrolase; therefore, production of leukotriene B4 (LTB4) in biological fluids provides a direct measure of the pharmacodynamic (PD) response to acebilustat treatment. Here we compare the pharmacokinetics (PK) and PD between CF patients and healthy volunteers, and investigate the food effect and CYP3A4 induction in healthy volunt  ...[more]

Similar Datasets

Unknown Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies.
| S-EPMC6106189 | biostudies-literature
Unknown Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study.
| S-EPMC5599956 | biostudies-literature
Unknown Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.
| S-EPMC3583342 | biostudies-literature
Unknown Effects of Food, Gastric Acid Reduction, and Strong CYP3A Induction on the Pharmacokinetics of Tasurgratinib, a Novel Selective Fibroblast Growth Factor Receptor Inhibitor.
| S-EPMC11591400 | biostudies-literature
Unknown Randomized, double-blind, phase 1a single-ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers.
| S-EPMC11413051 | biostudies-literature
Unknown Phase I studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS-1211, a tissue-nonspecific alkaline phosphatase inhibitor.
| S-EPMC9010257 | biostudies-literature
Unknown Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
| S-EPMC7027746 | biostudies-literature
Unknown Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.
| S-EPMC5595971 | biostudies-other
Unknown Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics.
| S-EPMC9292001 | biostudies-literature
Unknown Association between Food/UGT2B7 Polymorphisms and Pharmacokinetics/Pharmacodynamics Properties of Indapamide in Healthy Humans.
| S-EPMC10216553 | biostudies-literature